Page last updated: 2024-11-06

avridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Avridine is a natural product isolated from the plant *Avicennia marina*. It exhibits potent anti-inflammatory activity, particularly against nitric oxide (NO) production. Research suggests that avridine's anti-inflammatory mechanism involves inhibiting the activation of nuclear factor kappa B (NF-κB), a key regulator of inflammation. Furthermore, avridine has shown promising activity against cancer cell lines, suggesting its potential as a cancer therapeutic agent. Due to its biological activities, avridine has attracted significant research interest for its potential therapeutic applications in various inflammatory and cancer-related conditions. However, studies on avridine's pharmacological effects are still ongoing, and further investigations are needed to fully understand its therapeutic potential and safety profile.'

Cross-References

ID SourceID
PubMed CID37186
CHEMBL ID2106042
CHEBI ID188846
SCHEMBL ID75889
MeSH IDM0048700

Synonyms (47)

Synonym
auridine
cp-20961
2-[3-(dioctadecylamino)propyl-(2-hydroxyethyl)amino]ethanol
n,n-dioctadecyl-n',n'-bis(2-hydroxy-ethyl)propanediamine
cp-20,961
35607-20-6
D03017
avridine (usan)
avridine [usan:inn]
ethanol, 2,2'-((3-(dioctadecylamino)propyl)imino)bis-
avridina [spanish]
2,2'-((3-(dioctadecylamino)propyl)imino)bisethanol
2,2'-((3-(dioctadecylamino)propyl)imino)diethanol
avridine
brn 2227682
cp 20961
n,n-dioctadecyl-n',n'-bis(2-hydroxyethyl)propanediamine
avridinum [latin]
FT-0662340
CHEBI:188846
HMS3263J13
CHEMBL2106042
avridina
avridinum
p9j7o7ynsw ,
unii-p9j7o7ynsw
n,n-dioctadecyl-n',n'-bis(2-hydroxyethyl)-1,3-diaminopropane
avridine [inn]
avridine [usan]
CCG-222470
SCHEMBL75889
NCGC00261851-01
tox21_501166
WXNRAKRZUCLRBP-UHFFFAOYSA-N
n,n-dioctadecyl-n',n'-bis(2-hydroxyethyl)-1,3-propanediamine
2,2'-(3-(dioctadecylamino)propylazanediyl)diethanol
AKOS024457794
DTXSID70189078
SR-01000898792-1
sr-01000898792
avridine, >=97% (hplc)
HY-107634
2,2'-((3-(dioctadecylamino)propyl)azanediyl)bis(ethan-1-ol)
CS-0029034
Q27286421
STARBLD0009528
E87339

Research Excerpts

Overview

Avridine is a potent synthetic adjuvant that can induce arthritis is most rat strains.

ExcerptReferenceRelevance
"Avridine is a potent synthetic adjuvant that can induce arthritis is most rat strains. "( Avridine-induced arthritis in rats; a T cell-dependent chronic disease influenced both by MHC genes and by non-MHC genes.
Holmdahl, R; Jonsson, R; Vingsbo, C, 1995
)
3.18

Treatment

ExcerptReferenceRelevance
"Pre-treatment by avridine had little effect on interferon levels over that induced by virus alone, but that did not explain the enhancement of tumor growth since NK activity was increased.(ABSTRACT TRUNCATED AT 250 WORDS)"( Opposing effects of the interferon inducer, avridine: enhancement or suppression of tumor growth depending on treatment regimen.
Koller, LD; Talcott, PA; Whitbeck, GA; Woodard, LF, 1986
)
0.86

Dosage Studied

ExcerptRelevanceReference
" Dose-response curves demonstrated a close relationship between the inhibitory effects of DXS on the DTH and the A-PE/DDA complex formation."( Suppression of the cellular adjuvanticity of lipophilic amines by a polyanion.
Hilgers, LA; Jansze, M; Snippe, H; van Vliet, KE; Willers, JM, 1986
)
0.27
" Three dosage levels of ascorbic acid (10 mg/kg, 20 mg/kg, and 40 mg/kg) were examined for their effects on neutrophil function in cattle treated with dexamethasone (0."( In vivo effect of ascorbic acid on neutrophil function in healthy and dexamethasone-treated cattle.
Kaeberle, ML; Roth, JA, 1985
)
0.27
" A single dosage (0."( Synthetic immunomodulators for prevention of fatal infections in a burned guinea pig model.
Alexander, JW; Gonce, SJ; Loose, LD; Miskell, P; Stinnett, JD; Tenney, CL, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
amino alcoholAn alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (66)

TimeframeStudies, This Drug (%)All Drugs %
pre-199033 (50.00)18.7374
1990's26 (39.39)18.2507
2000's2 (3.03)29.6817
2010's3 (4.55)24.3611
2020's2 (3.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.60

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.60 (24.57)
Research Supply Index4.26 (2.92)
Research Growth Index4.68 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.60)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (5.71%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other66 (94.29%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]